Skip to content

Mineralys Therapeutics

US · MLYS #2760 by market cap Listed 2023
13.66 -0.50 -3.53%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 4 in the most recent period (2026/Q3).
  • Total institutional ownership rose 0.1 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
115.89% +0.12pp
Institutions
294 +4
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund49.87%
VC/PE Fund31.66%
Hedge Fund26.98%
Public Company4.38%
Private Company1.49%
Sovereign Wealth Fund0.93%
Individual/Insider0.51%
Government Pension Fund0.32%
Insurance Company0.14%

Top holders as of 2026-09-30

Catalys Pacific 8.81% · 7.80M sh
RA Capital Management, L.P. 8.69% · 7.69M sh
BlackRock 6.97% · 6.17M sh
Samsara BioCapital LLC 6.63% · 5.87M sh
FMR 5.32% · 4.71M sh
Deerfield Management Company, L.P. 4.47% · 3.96M sh
Vanguard Capital Management, LLC 3.36% · 2.97M sh
State Street Global Advisors 3.25% · 2.88M sh
Capital Research 2.90% · 2.57M sh
T. Rowe Price Group, Inc. 2.56% · 2.26M sh
Laurion Capital Management LP 2.80% · 2.48M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 7 buys · 43 sells

NameRoleStake
Jon Congleton Chief Executive Officer 0.44%
Eric Warren Chief Commercial Officer 0.04%
David Rodman Former Chief Medical Officer 0.01%
Daphne Karydas Independent Director 0.01%
Adam Levy Chief Financial Officer 0.00%
Glenn Sblendorio Independent Chairperson --
Srinivas Akkaraju Independent Director --
Kristine Peterson Director --
James Ferguson Chief Medical Officer --
RA Capital Management, L.P. -- --
Lonnel Coats Director --
Alexander Gold Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-18 Kristine Peterson Director Other Acquisition +12,400 --
2026-10-18 Kristine Peterson Director Other Derivative Acquisition +16,600 $20.92
2026-10-18 Lonnel Coats Director Other Acquisition +12,400 --
2026-10-18 Lonnel Coats Director Other Derivative Acquisition +16,600 $20.92
2026-10-12 David Rodman Former Chief Medical Officer Intent to Sell (Form 144) -3,542 $22.04
2026-09-29 Jon Congleton Chief Executive Officer Automatic Disposition -75,000 $25.46
2026-09-21 Catalys Pacific -- Open Market Disposition -104,320 $28.81
2026-09-20 Eric Warren Chief Commercial Officer Derivative Exercise and Sale -7,438 $13.24–28.12
2026-09-16 David Rodman Former Chief Medical Officer Intent to Sell (Form 144) -417 $27.95
2026-09-14 Daphne Karydas Independent Director Derivative Exercise and Sale -3,000 $12.02–28.58
2026-09-13 David Rodman Former Chief Medical Officer Intent to Sell (Form 144) -7,709 $28.14
2026-09-08 David Rodman Former Chief Medical Officer Intent to Sell (Form 144) -2,171 $30.87
2026-08-20 Eric Warren Chief Commercial Officer Derivative Exercise and Sale -7,437 $13.24–25.98
2026-08-16 David Rodman Former Chief Medical Officer Intent to Sell (Form 144) -417 $25.46
2026-08-12 David Rodman Former Chief Medical Officer Intent to Sell (Form 144) -14,056 $26.48
2026-08-09 James Ferguson Chief Medical Officer Other Acquisition +102,400 --
2026-08-09 James Ferguson Chief Medical Officer Other Derivative Acquisition +135,000 $27.38
2026-08-09 David Rodman Former Chief Medical Officer Derivative Exercise and Sale -2,170 $16.00–27.09
2026-07-20 Eric Warren Chief Commercial Officer Derivative Exercise and Sale -7,438 $13.24–26.87
2026-07-16 David Rodman Former Chief Medical Officer Derivative Exercise and Sale -416 $15.44–26.53

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Mineralys Therapeutics discussion 0 comments

Add a comment